Key facts
- Valanx Biotech’s last known valuation is $2.9M (Jan 2020).
- It has raised $7.0M; the latest was Later Stage VC ($3.5M) in Mar 2026.
- Notable investors include SOSV, Austria Wirtschaftsservice, Bundesministerium für Digitalisierung und Wirtschaftsstandort, Bundesministerium für Innovation, Fournier-Majoie Foundation — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Valanx Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Valanx Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Valanx Biotech
Developer of a protein conjugation technology designed to enable the creation of next-generation drug conjugates for therapeutic applications. The company develops a proprietary platform that allows site-specific protein conjugation across multiple positions within antibodies and proteins using rapid click-chemistry processes, enabling pharmaceutical developers to produce homogeneous drug conjugates with improved stability, pharmacokinetics, and therapeutic performance for biologic treatments.
- Sector
- Healthcare
- HQ
- Vienna, Austria
- Founded
- 2017
- Employees
- 15
- Website
- valanx.bio/
- Ownership
- Privately Held (backing)
Valanx Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Valanx Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Valanx Biotech in its N-PORT filings yet. We sweep new filings monthly.